Podcasts about fasn

In celebration of Donate Life month, we are sharing a special crossover episode from NKF's Life as a Nephrology Professional podcast. Tune in and hear from three living kidney donors as they discuss the power of living donation and kidney advocacy. Host: Anna Gaddy, MD, FASN, FNKF Guests: Lauren Drew, JD, Beth Burbridge   Additional Resources: Becoming a Living Donor NKF Advocacy   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Carla M. Nester, MD, MSA, FASN - Closing the Diagnostic Gap: Quick Fire Essentials in C3G and IC-MPGN

Carla M. Nester, MD, MSA, FASN - Closing the Diagnostic Gap: Quick Fire Essentials in C3G and IC-MPGN

In this episode, Martina McGrath, MD, FASN, talks with guest editors Laurence H. Beck, Jr., MD, PhD, and Joyita Bharati, MD, about their editorial "A Renaissance of Clinical Trials for IgA Nephropathy" from nephSAP, Vol. 24, No.1 on glomerular diseases.

In this episode, Martina McGrath, MD, FASN, talks with guest editors Laurence H. Beck, Jr., MD, PhD, and Joyita Bharati, MD, about their editorial "A Renaissance of Clinical Trials for IgA Nephropathy" from nephSAP, Vol. 24, No.1 on glomerular diseases.

This week's expert, Hepatologist and Key Opinion Leader Mazen Noureddin, joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. First, Mazen discusses a tremendously exciting group of FGF-21 agents, specifically mentioning Akero Therapeutics's efruxifermin, 89bio's pegozafermin, and Boston Pharmaceuticals's efimosfermin. He points to efruxifermin's 96-week results to suggest that FGF-21s might be appropriate for a wide range of patients, the idea that the drug's duration of effect may make the idea of “induction therapy” less appropriate, and the exciting early data on cirrhosis patients. He also mentions pegozafermin's publication of data in the New England Journal of Medicine and efimosfermin's promising data based on monthly dosing. Next, Mazen provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. Finally, Mazen discusses other promising compounds in later-stage development, including the pan-PPAR lanifibranor and the FASN inhibitor denifenstat. He notes ongoing work on new classes and combination therapies. 

00:00:00 - Surf's Up: Season 6 Episode 4 Surfing the MASH Tsunami concludes its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on pivotal messages that attendees took away from the conference and what messages they would like to share with listeners. Our newsmaker, Fatty Liver Alliance and CEO Mike Betel, discusses the lessons he has taken from being invited to a far wider swath of conferences this year and shares the messages he delivers to these new audiences. Finally, our expert, hepatology research and key opinion leader Mazen Noureddin, discusses recent advances in drug development, focusing on agents in Phase 3 trials.00:04:24 - IntroductionHost Roger Green briefly describes this episode's three sections and one key lesson from each.00:06:03 - Roundtable: Highlights from the AASLD Emerging Trends Conference, Part 4This is the concluding portion of our Emerging Trends Conference Roundtable. The group focuses on key lessons they have learned and messages they would like listeners to take from this conversation.  The pivotal idea is that SLD is a spectrum running from MASLD through MetALD to ALD. Researchers and treaters will all do best in developing and implementing therapies and guidelines with this thought in mind. Aleksander Krag stresses this idea and notes that, with several different classes of drugs demonstrating positive impact, it will be an exciting decade ahead as we learn how to apply these drugs along the spectrum. Jenn Jones and Alex Lalos note the importance of identifying MetALD, although Jenn noted that it does not seem wise to conduct trials solely with MetALD patients at this time.  00:22:04 - Newsmaker: Mike Betel on the Increased Visibility of Patient AdvocatesThis week's newsmaker, Mike Betel, has experienced a significant increase in the number of conferences at which he is invited to speak or appear on a panel. This discussion centers around the reasons Mike believes this is happening and the message(s) he delivers. To Mike, his most important contribution lies in the amount of information he sends back from each event, many of which surpass 30% download rates (and some even hit 50%). He discusses his value in diabetes, endocrinology and obesity meetings, where he brings a "liver" perspective and co-education opportunity to these events. The entire experience has taught him about the need not to stigmatize patients and reinforced his belief in the importance of tailoring care to patients' needs and personalities. 00:49:28 - Expert: Mazen Noureddin on the Exciting MASLD Drug Development EnvironmentHepatologist and Key Opinion Leader Mazen Noureddin joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. Specifically, he discusses the FGF-21 agents, the range of patients for whom they might be appropriate, how efruxifermin's 96-week results may make the idea of "induction therapy" less appropriate,  and the exciting early data on cirrhosis patients. He provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. He goes on to discuss the pan-PPAR lanifibranor, the FASN inhibitor denifenstat, and notes ongoing work on new classes and combination therapies. In general, he paints, I think, not a rosy, but an extremely optimistic picture of what the future will be for patients who need to be treated for fatty liver. 01:09:38 - Business Report Roger discusses the next Roundtable and provides some details on SurfingMASH's coverage of the upcoming EASL Congress.

Die Basler Fasnacht ist seit 2017 UNESCO-Weltkulturerbe. Nun hat eine Gruppe Fasnächtlerinnen und Fasnächtler die Initiative ergriffen dieses Kulturgut digital zu archivieren. Gestern Abend fand ein erster Info-Anlass statt, zu dem Fasnachtsgruppen eingeladen waren. Ausserdem: - Mövenpick Restaurant am Basler Marktplatz wird umgebaut - Chef des Frauenteams beim FCB geht - Brand in Laufen

Mark Houston welcomes David Kovaleski, M.D., FASN, Critical Care Doctor at Rapid City Hospital, and a true Renaissance man. Dr. Kovaleski recounts his journey to becoming an ICU Physician, relates the challenges of Critical Care and touches on the delicate nature of end-of-life discussions. Beyond the ICU, Dr. Kovaleski, a passionate painter and photographer, credits creativity with helping him navigate the intense nature of Critical Care. He shares his Western-themed artwork and his upcoming portrait series, which features medical professionals.To learn more about Dr. Kovaleski's artwork, visit www.kovaleskiphoto.com Hosted on Acast. See acast.com/privacy for more information.

The Infection Prevention & Transitions of Care is a four-part series developed by the ASN Nephrologists Transforming Dialysis Safety (NTDS) initiative, led by Dr. Tushar Chopra. In episode one, experts discuss infection prevention and dialysis challenges.

The Infection Prevention & Transitions of Care is a four-part series developed by the ASN Nephrologists Transforming Dialysis Safety (NTDS) initiative, led by Dr. Tushar Chopra. In episode one, experts discuss infection prevention and dialysis challenges.

Mit dem Motto «Syg wie de wottsch» stellt das «Fasnachts-Comité» das Selbstbestimmungsrecht des Menschen in einen fasnächtlichen Kontext. Ob und wie die Schnitzelbänggler und Zeedeldichterinnen dieses Thema aufgreifen, wird sich an den «Drey scheenschte Dääg» und drumherum herausstellen. Wer diese Sendung am Radio hören will:  Montag, 17.03.2025, 20.03 Uhr, Radio SRF 1 Die individuelle Freiheit ist seit jeher ein Markenzeichen der Basler Fasnacht. Und aller anderen Traditionsfasnachten auch. Aber durch die Betonung der Satire, des Widerspruchs und des Andersseins, wie sie in Basel nicht nur durch «Schnitzelbängg» und andere charakteristische Eigenheiten gepflegt werden, sondern auch von jedem einzelnen Fasnächtler und jeder einzelnen Fasnächtlerin, bekommt sie hier doch eine besondere Bedeutung. Wie die Baslerinnen und Basler in diesem Jahr ihre Freiheit nutzen, welche Pointen sie finden und welche Themen sie sonst noch behandeln, zeigt der traditionelle Querschnitt, den Michael Luisier für SRF präsentiert. ____________________ Mit: Michael Luisier und vielen Beteiligten der Basler Fasnacht 2025 ____________________ Redaktion: Michael Luisier ____________________ Produktion: SRF 2025 ____________________ Dauer: ca. 50'

Mit dem Motto «Syg wie de wottsch» stellte das Fasnachts-Comité das Selbstbestimmungsrecht des Menschen in einen fasnächtlichen Kontext. Ob und wie dieses Thema auch von den Schnitzelbängglern und Zeedel-Dichter aufgenommen wurde, hat sich an der Fasnacht gezeigt. Die individuelle Freiheit ist seit jeher ein Markenzeichen der Basler Fasnacht. Und aller anderen auch. Aber durch die Betonung der Satire, des Widerspruchs und des Anderssein, wie sie in Basel nicht nur durch «Schnitzelbängg» und anderen «Fasnachts-Disziplinen» gepflegt werden, sondern auch von jedem einzelnen Fasnächtler und jeder einzelnen Fasnächtlerin, bekommt sie hier doch eine besondere Bedeutung. Wie die Baslerinnen und Basler in diesem Jahr ihre Freiheit nutzen, welche Pointen sie finden und welche Themen sie sonst noch behandeln, zeigt der «Querschnitt durch die Basler Fasnacht».

Mit dem Motto «Syg wie de wottsch» stellt das «Fasnachts-Comité» das Selbstbestimmungsrecht des Menschen in einen fasnächtlichen Kontext. Ob und wie die Schnitzelbänggler und Zeedeldichterinnen dieses Thema aufgreifen, wird sich an den «Drey scheenschte Dääg» und drumherum herausstellen. Auf Mundart Wer diese Sendung am Radio hören will:  Montag, 17.03.2025, 14.00 Uhr, Radio SRF 1 Die individuelle Freiheit ist seit jeher ein Markenzeichen der Basler Fasnacht. Und aller anderen Traditionsfasnachten auch. Aber durch die Betonung der Satire, des Widerspruchs und des Andersseins, wie sie in Basel nicht nur durch «Schnitzelbängg» und andere charakteristische Eigenheiten gepflegt werden, sondern auch von jedem einzelnen Fasnächtler und jeder einzelnen Fasnächtlerin, bekommt sie hier doch eine besondere Bedeutung. Wie die Baslerinnen und Basler in diesem Jahr ihre Freiheit nutzen, welche Pointen sie finden und welche Themen sie sonst noch behandeln, zeigt der traditionelle Querschnitt, den Michael Luisier für SRF präsentiert. ____________________ Mit: Michael Luisier und vielen Beteiligten der Basler Fasnacht 2025 ____________________ Redaktion: Michael Luisier - Produktion: SRF 2025 - Dauer: ca. 50'

Während Tausende Fasnächtlerinnen und Fasnächtler trommeln und pfeifen, herrscht bei Basler Instrumentenbauern Hochbetrieb. Alleine beim Trommelspezialist Schlebach im Kleinbasel werden pro Tag 30 bid 40 "Kessel" geflickt. Viel zu tun gibt es vor allem am Dienstag.

Auch am Mittwoch zogen wieder Tausende Fasnächtlerinnen und Fasnächtler durch die Basler Innenstadt. Wegen des eher nassen Wetters hatte es am zweiten Cortège jedoch deutlich weniger Publikum. Ausserdem: · 99 Jahre Jeisi-Migger · Fasnachtsgast: -minu

Das sagt der Musiker, Mitbegründer der «Lovebugs», Sozialtherapeut und Fasnächtler Sebastian Hausmann, wenn man ihn nach der Basler Fasnacht fragt. Die betreibt er genauso leidenschaftlich wie seinen Musikerberuf. Sebastian (Baschi) Hausmann spielt Gitarre und Bass. Er singt und schreibt seit seinem 13. Lebensjahr Songs. Geboren wird er als Sohn des Basler Hörspielregisseurs Hans Hausmann. Seine Mutter ist Engländerin. Von Anfang an ist er also zweisprachig unterwegs. Englisch und Baseldeutsch. Viele Jahre verbringt er in England. Zuerst als Student eines Colleges für Rock- und Popmusik, dann als Musiker und Theatertechniker in London, wo er die Sängerin Hazel O'Connor kennenlernt, mit der er auf Tournee geht. Nach Jahren in England und den USA beschliesst er, nach Basel zurückzukehren und die Musik an den Nagel zu hängen. Der Plan scheitert. Er gründet neue Bands, darunter die «Lovebugs» und «Fucking Beautiful», arbeitet seit 15 Jahren in einer Kontakt- und Anlaufstelle für Drogensüchtige und geht gleichzeitig weiteren musikalischen Projekten nach. All das tut er mit beispielloser Leidenschaft. Genauso leidenschaftlich wie er die Basler Fasnacht betreibt. Als stadtbekannter Tambourmajor eines «Schyssdräggzüglis», der tanzend durch die Gassen zieht. Und in diesem Jahr auch als Darsteller in einer grossen Basler Vorfasnacht, wo er – wen wundert's – einen höchst musikalischen Tambourmajor spielt. Die Musiktitel: 1. October - Fools of War (Maria Laschinger, Tamara Kämpfer, Tom Gschwind und Sebastian Hausmann) 2. PJ Harvey - Let England Shake 3. David Bowie - Life on Mars 4. Crosby, Stills, Nash & Young - Carry on 5. The Last Dinner Party - My Lady of Mercy

Der FCB auf Meisterkurs - werden die Basler jetzt wieder «arrogant» (Carlos Varela)? Und seit wann ist Xherdan Shaqiri eigentlich Fasnächtler? Ausserdem: Fahren die Yakins den FC Schaffhausen an die Wand, und kehrt beim FCZ je wieder Ruhe ein? «Sykora Gisler», der Fussball-Podcast von SRF 3-Moderator Tom Gisler und «ZWÖLF»-Chefredaktor Mämä Sykora bietet unterhaltende Gespräche mit Haltung, Herz und einer guten Prise Humor. Zu den beiden Enthusiasten stösst jeweils ein prominenter Gast – der das Duo mit scharfer Zunge und genauso viel Fussballherz ergänzt.

Die Zuger Kantonalbank plant ihren Geschäftssitz an der Baarerstrasse in Zug aufzustocken. Das 1982 erbaute Gebäude zwischen dem Bahnhof und dem Einkaufszentrum Metalli soll um vier Stockwerke in die Höhe wachsen. Weiter in der Sendung: · Der Luzerner Regierungsrat will kein generelles Handyverbot an den Schulen. · Das schöne Wetter lockte mehrere Zehntausend Fasnächtlerinnen und Fasnächtler auf die Strassen.

Die Stadt Luzern hat bei der Sicherheit an der Fasnacht dieses Jahr aufgerüstet: Zum ersten Mal kamen Kameras und künstliche Intelligenz zum Einsatz, um gefährliche Situationen in den Gassen zu verhindern. Laut den Verantwortlichen und den Fasnächtlern hat sich der Aufwand gelohnt. Weiter in der Sendung: · Die Obwaldner Unternehmerin Christiane Leister ist 69-jährig gestorben. · Bundesrätin Karin Keller-Sutter ist Festrednerin an der 1.-August-Feier auf dem Rütli. · Der 99-jährige Robert Beul ist das älteste Mitglied der Rotseezunft Ebikon.

Mit der Weytagwache ist die Zentralschweizer Fasnacht am Morgen um 6 Uhr in die nächste Runde gestartet. Am heutigen Güdismontag erwartet die Fasnächtlerinnen und Fasnächtler ein Tag bei herrlich sonnigem Wetter. Weiter in der Sendung: · Der FC Luzern schafft gegen Yverdon spät die Wende vom 0:2 zum 2:2. · Die Stiftung pro jungwacht blauring unterstützt die Scharen bei ausserordentlichen Anschaffungen.

Der 28-jährige Luzerner Tim Meier ist begeisterter Fasnächtler. Meist ist er aber selber unverkleidet unterwegs - dafür mit Kamera, Gimbal und Handy. Er fängt die schönsten Bilder der Luzerner Fasnacht ein. So trägt er das närrische Treiben in die ganze Welt hinaus. Weiter in der Sendung: · Fasnächtlich unterwegs mit der Guggenmusik Chottlebotzer · 26'000 Leute verfolgten den Fritschiumzug am Schmutzigen Donnerstag. · Die geplante Windenergieanglage auf dem Stierenberg in Rickenbach LU wird zum Gerichtsfall.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Sumit Mohan, MD, MPH, FASN, and Winfred Williams, MD, to discuss "Racial Inequalities in Access to Kidney Transplantation" from nephSAP Vol. 23, No. 5, Transplantation.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Sumit Mohan, MD, MPH, FASN, and Winfred Williams, MD, to discuss "Racial Inequalities in Access to Kidney Transplantation" from nephSAP Vol. 23, No. 5, Transplantation.

Cannabis or marijuana is becoming increasingly more popular in the United States for recreational and medical use. What is cannabis? Are there benefits to using it? Is it ok for someone with kidney disease or dialysis to use it? Learn all this and more in today's episode. Joshua Rein, DO, FASN, is a board-certified nephrologist, kidney physiologist, and certified hypertension specialist. He is an Assistant Professor in the Barbara T. Murphy Division of Nephrology in the Department of Medicine at the Icahn School of Medicine at Mount Sinai in NYC and a Staff Physician at the James J. Peters, Veterans Affairs Medical Center. He received his medical degree from the New York College of Osteopathic Medicine, completed internal medicine at Mount Sinai Beth Israel, and completed clinical and research nephrology fellowships at Mount Sinai Hospital. Dr. Rein is interested in the effects of cannabis and cannabinoids on kidney health and disease given their widespread growing popularity despite an uncertain impact on health. Dr. Rein's research, funded by a Veterans Affairs Career Development Award, utilizes preclinical animal models to characterize the kidney endocannabinoid system and examine the physiological impact of cannabinoids on the regulation of fluid and electrolyte balance by the kidney. His clinical research focuses on the risks, benefits, and clinical significance of cannabis consumption among people with kidney disease and those at risk for developing kidney disease.   Additional Resources: Nephrologist's Guide to Cannabis Cannabis Usage Study AJKD Blog   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

This episode is brought to you by BiOptimizers, Levels, and Air Doctor. What if there was one key nutrient that could boost your health, increase longevity, reduce chronic inflammation, and lower your risk of Alzheimer's? You've probably heard of it: omega-3! But here's the surprising part—over 90% of the population has suboptimal omega-3 levels. Today on The Dhru Purohit Show, we're revisiting one of our favorite episodes with Dr. Bill Harris, a world-renowned researcher, to dive into decades of research on omega-3s and their powerful impact on health. Dr. Harris explains the correlation between optimal omega-3 levels and longer life spans, reduced rates of depression, anxiety, and Alzheimer's, as well as their role in lowering chronic inflammation. As one of the most researched nutrients—and among the top three that can drastically improve health—omega-3s are essential. In this episode, Dr. Harris shares insights on choosing quality fish and supplements, understanding optimal omega-3 levels, and testing your levels through the OmegaQuant Institute. If you're looking for inspiration to prioritize omega-3s in your diet, this conversation is a must-listen! William S. Harris, PhD, FASN, has been a leading researcher in the field of omega-3 fatty acids for 40 years. He has authored over 300 scientific papers on fatty acids and health, served on the faculty of three medical schools, and received five NIH grants to study omega-3s. Dr. Harris co-authored three American Heart Association (AHA) statements on fatty acids and heart health. As the co-inventor of the Omega-3 Index and other omega-3 blood tests, as well as the founder of OmegaQuant Analytics, Dr. Harris has been ranked among the top 2% of scientists worldwide for the impact of his research. In this episode, Dhru and Dr. Harris dive into: Higher levels of omega-3's lead to a longer life (00:00:35) Omega-3s are in the top three nutrients that can improve our health (3:00) Mindblowing research on smokers and the protective nature of omega-3s (5:25) The link between low omega-3s, depression, mood, and anxiety (16:12)  High levels of omega-3s and their correlation to reducing the risk for dementia and Alzheimer's (20:21) The research behind omega-3's and reducing chronic inflammation (28:32)  The average omega-3 levels versus optimal levels (30:45)  What has led to omega-3 deficiencies and the rise in ultra-processed food consumption (31:10)   Reducing triglyceride levels with fish oil and the impact on our cells (32:43)  What are EPA, DHA, and ALA, and the sources of each (36:35) How much fish consumption is optimal, and what kind (44:40) Testing your levels via the Omega-3 index and optimal ranges (49:40) Choosing the right fish oil and general dosage (59:10)  Testing pregnant women and children (1:22:40)  Why the omega-3s aren't being tested for and prescribed by every doctor (1:26:00)  Also mentioned in this episode: Testing via OmegaQuant Fatty Acid Research Insitute  For more on Dr. Harris, follow OmegaQuant via Instagram, Twitter, and Facebook.  This episode is brought to you by BiOptimizers, Levels, and Air Doctor. Go to bioptimizers.com/dhru now and enter promo code DHRU10 to get 10% off any order and up to 2 travel-size bottles of Magnesium Breakthrough for a limited time. Right now, Levels is offering my listeners an additional 2 FREE months of the Levels annual Membership when you use my link, levels.link/DHRU. Make moves on your metabolic health with Levels today.  AirDoctor is offering my community $300 off. Just go to dhrupurohit.com/filter/ to clean up your home's air and feel better today.  Learn more about your ad choices. Visit megaphone.fm/adchoices

You will NOT want to miss this episode with dietitian researcher Annabel Birute PhD, RD, FNKF, FASN. She and Melanie talk about how gut bacteria can impact kidney health - both for the good AND bad and what you can do to support a kidney-friendly gut microbiome! Connect with Annabel on LinkedIn and X.   Submit a question for Melanie to answer on the podcast! Connect with The Kidney Dietitian! Work with Us! |  Instagram | Facebook | Pinterest | Facebook Group | Newsletter www.thekidneydietitian.org All information in this podcast is meant for educational purposes only and should not be used in place of advice from a medical professional.  

Carla M. Nester, MD, MSA, FASN - Novel Therapies in Focus: Updates in C3 Glomerulopathy and IC-MPGN

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN speak with guest editors Paul E. Stevens MD and Adeera Levin MD to discuss their editorial "Chronic Kidney Disease Coming of Age" from nephSAP Volume 23, Number 4, Chronic Kidney Disease.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN speak with guest editors Paul E. Stevens MD and Adeera Levin MD to discuss their editorial "Chronic Kidney Disease Coming of Age" from nephSAP Volume 23, Number 4, Chronic Kidney Disease.

Swapnil Hiremath, MD, MPH, FASN, joins Hiddo Heerspink, PhD, and Meg Jardine, MBBS, PhD, to discuss clinical trials presented at Kidney Week 2024, including notable findings from accepted submissions and late-breaking clinical trial sessions.

Swapnil Hiremath, MD, MPH, FASN, joins Hiddo Heerspink, PhD, and Meg Jardine, MBBS, PhD, to discuss clinical trials presented at Kidney Week 2024, including notable findings from accepted submissions and late-breaking clinical trial sessions.

Kidney Week 2024 on the go. Gentzon Hall, MD, PhD, FASN, Matthias Kretzler, MD, and Heather Reich, MD, PhD, discuss progress in glomerular disease research, emerging trends, and clinical challenges.

Leading health care professionals Edwina A. Brown, MD, MBChB, Timothy Ray, CNN, CNN-NP, DNP, NP, and Monnie Wasse, MD, MPH, FASN, share their perspectives on evolving advances in dialysis treatments and patient care in the US and across the globe.

Leading health care professionals Edwina A. Brown, MD, MBChB, Timothy Ray, CNN, CNN-NP, DNP, NP, and Monnie Wasse, MD, MPH, FASN, share their perspectives on evolving advances in dialysis treatments and patient care in the US and across the globe.

Kidney Week 2024 on the go. Gentzon Hall, MD, PhD, FASN, Matthias Kretzler, MD, and Heather Reich, MD, PhD, discuss progress in glomerular disease research, emerging trends, and clinical challenges.

David Happel is President and CEO of Sagimet Biosciences, a company developing drugs to treat metabolic diseases by targeting the underlying cause of fat accumulation in the liver. The drug denifanstat limits the activity of fatty acid synthase (FASN), an enzyme that regulates fat accumulation. This approach is a fat inhibitor, not a fat burner, the focus of other MASH drugs.  David explains, "Sagimet was founded back in 2007 as a private company with a group of medicinal chemists that had a particular target in mind, and this particular target was called fatty acid synthase, or FASN. FASN is a rather ubiquitous enzyme throughout the body that functions as a regulating enzyme in many organs. When FASN becomes overactive or overexpressed, it sort of throws things out of balance and, in particular, certain cardiometabolic diseases, such as MASH and in the liver. So, this group of chemists, in order to resolve this overactivity, developed a portfolio of FASN inhibitors, led by our lead program denifanstat, that seek to target the underlying cause of MASH and, therefore, really work to limit the activity of FASN, try to normalize it essentially is what we do." "For us and this particular molecule, it offers a differentiated approach to treating the disease for us and this particular molecule. Our molecule, denifanstat, is the only FASN inhibitor. It's the only fat inhibitor in development for MASH, making it rather unique. All the rest of the molecules or fat burners, fat oxidizers, and fat mobilizers include GLPs, FGF, and THR-beta. They all function by trying to burn fat peripherally and in the liver to a degree. They rely on that fat-burning mechanism to translate into reductions, inflammation, and fibrosis, which is important to treating MASH, but they've had varying degrees of success. Our molecule targets each pathway independently: fat, inflammation, and fibrosis, and has had a rather pronounced treatment effect as a result."  #SagimetBiosciences #MASH #FattyLiverDisease #FASN #FASNInhibitor #Fibrosis #Obesity #NASH #GLP1Agonists sagimet.com Download the transcript here

David Happel is President and CEO of Sagimet Biosciences, a company developing drugs to treat metabolic diseases by targeting the underlying cause of fat accumulation in the liver. The drug denifanstat limits the activity of fatty acid synthase (FASN), an enzyme that regulates fat accumulation. This approach is a fat inhibitor, not a fat burner, the focus of other MASH drugs.  David explains, "Sagimet was founded back in 2007 as a private company with a group of medicinal chemists that had a particular target in mind, and this particular target was called fatty acid synthase, or FASN. FASN is a rather ubiquitous enzyme throughout the body that functions as a regulating enzyme in many organs. When FASN becomes overactive or overexpressed, it sort of throws things out of balance and, in particular, certain cardiometabolic diseases, such as MASH and in the liver. So, this group of chemists, in order to resolve this overactivity, developed a portfolio of FASN inhibitors, led by our lead program denifanstat, that seek to target the underlying cause of MASH and, therefore, really work to limit the activity of FASN, try to normalize it essentially is what we do." "For us and this particular molecule, it offers a differentiated approach to treating the disease for us and this particular molecule. Our molecule, denifanstat, is the only FASN inhibitor. It's the only fat inhibitor in development for MASH, making it rather unique. All the rest of the molecules or fat burners, fat oxidizers, and fat mobilizers include GLPs, FGF, and THR-beta. They all function by trying to burn fat peripherally and in the liver to a degree. They rely on that fat-burning mechanism to translate into reductions, inflammation, and fibrosis, which is important to treating MASH, but they've had varying degrees of success. Our molecule targets each pathway independently: fat, inflammation, and fibrosis, and has had a rather pronounced treatment effect as a result."  #SagimetBiosciences #MASH #FattyLiverDisease #FASN #FASNInhibitor #Fibrosis #Obesity #NASH #GLP1Agonists sagimet.com Listen to the podcast here

Last night RTÉ’s Prime Time current affairs show examined the impact of drug debt on families. Contributors told how crime gang’s threatened to rape the sister of a young man who owed money to dealers. Another family had to leave Ireland. Jerry spoke to Jackie McKenna, project coordinator at FASN, Family Addiction Support Network. FASN, which is based in the North East, provides supports to families affected by addiction and drug debt.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, discuss with editor Ron Wald, MDCM, MPH, his editorial "Delivering Kidney Replacement Therapy in the ICU: Closing Evidence Gaps" from nephSAP Volume 23, Number 3.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, discuss with editor Ron Wald, MDCM, MPH, his editorial "Delivering Kidney Replacement Therapy in the ICU: Closing Evidence Gaps" from nephSAP Volume 23, Number 3.

On today's special episode of Hot Topics and Kidney Health we're sharing audio from a recent webinar hosted by National Kidney Foundation on kidney xenotransplantation. Stay tuned to hear from the experts and learn about the latest updates on animal-to-human transplantation.   Dr. Tatsuo Kawai is a professor of surgery at Harvard Medical School and the A. Benedict Cosimi Chair in Transplant Surgery at Massachusetts General Hospital. He is also director of the Legorreta Center for Clinical Transplantation Tolerance. He was awarded the Martin Research Prize at MGH in 2009 and the New Key Opinion Leader Award by the Transplantation Society in 2010 for this work. In the field of xenotransplantation, he has collaborated extensively with eGenesis over the past five years, achieving over two years of survival for genetically edited kidney xenografts in nonhuman primates, which was published in Nature in 2023. In March 2024, he successfully performed the world first kidney xenotransplantation from the pig with 69 genomic edits in a living patient with end stage renal disease.  Vineeta Kumar MD, FAST, FASN  is the lead nephrologist for the Living Kidney Donor and Incompatible Kidney Transplant programs at the University of Alabama in Birmingham. She is an expert in kidney transplantation, living kidney donation, incompatible kidney transplant, kidney paired donation and cardiovascular outcomes after kidney transplantation. Peter Reese, MD, PhD, is an NIH-funded transplant nephrologist and epidemiologist. His research focuses on: a) developing effective strategies to increase access to solid organ transplantation; b) improving the process of selecting and caring for living kidney donors; c) determining outcomes of health policies on vulnerable populations with renal disease, including the elderly; d) testing strategies to improve important health behaviors such as medication adherence; and e) transplant ethics. He was a recipient of a Presidential Early Career Award for Scientists and Engineers, was elected member of the American Society of Clinical Investigation, and was a Greenwall Faculty Scholar in bioethics. He is a past chair of the Ethics Committee for the United Network for Organ Sharing (UNOS), which oversees organ allocation and transplant regulation in the US, and is an Associate Editor for the American Journal of Kidney Diseases. He co-led the THINKER, USHER, MYTHIC, and SHELTER trials involving transplanting HCV-infected donor organs into uninfected recipients. His work has been generously funded by foundations and the NIH, including a K-24 to support mentoring.   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.  

Join us as Dr Ray Bignall (@DrRayMD) delves into the transformative power of mentorship in career development.  Learn to cultivate diverse mentor relationships, the importance of genuine connections, and navigating feedback across different identities. Whether you're a mentor or a mentee, this episode is packed with invaluable insights to help you thrive in your professional journey. Forgive us for taking the opportunity to be mentored by Dr Bignall for the first 20 minutes, if you really want to jump ahead to the case, it starts at 21:33. Sorry, no CME for this one! Show Segments Intro, disclaimer, guest bio Advice- slowing down, taking time during training and beyond, saying “not right now” 14:33 Picks of the Week 21:33 Case from Kashlak 22:05 Dr Bignall's Mentors 29:00 How Dr Bignall Approaches Mentorship/Coaching Trees 36:00 Mentoring across Identify Differences 48:15 Mentoring across Generational Differences 58:01 Helping Mentees Process Feedback 01:03:55 Continuous Improvement for Mentors 01:07:00 Take Home Points Credits Producer, show notes: Molly Heublein MD Infographic, Cover Art: Paige Spata MD Hosts, Script, Editors: Era Kryzhanovskaya MD, Molly Heublein MD    Guest: O. N. Ray Bignall II, MD, FAAP, FASN Technical support: Podpaste Theme Music: MorsyMusic 

00:00:00 Surf's Up, Season 5 Episode 20Naim Alkhouri and Mazen Noureddin join co-hosts Jörn Schattenberg and Roger Green to discuss major drug development stories from the EASL Congress 2024. They pay tribute to Stephen Harrison and proceed to groundbreakers.00:08:16 - Presentations on ResmetiromMazen shares a paper he presented looking at resmetirom dose-response. The 100mg dose performed better than the 80mg dose. Jörn notes that the most important element of the study might be the demonstrated 36-month effect.  00:14:19- Implications of Different Analytical Modes Naim compares different modes of analysis. Intent to Treat, which treats all non-completers as failures, will produce lower rates of response than a "completer" or "modified Intent to Treat" analysis, which either eliminates non-completers or assigns them placebo-level response. 00:16:12 - The "Twin-Cretins"Jörn coined  the name "Twin-cretins" for agents with GLP-1 agonism plus another incretin effect. Tirzepatide is a GLP/GIP while survodutide, pemvuditide, and efinopegdutide, are GLP/glucagons. Naim reviews the tirzepatide late-breaker presentation, which showed high rates of MASH resolution, but, as a completer analysis, might not have proven whether a GLP/GIP can achieve significant fibrosis regression.  Naim notes that Stephen doubted strongly this was possible, but that bariatric surgery's effect creates a paradox. Mazen concurs, and states he is more confident in the GLP/glucagon agents. Jörn agrees. 00:23:09 - Implications of widespread GLP useRoger asks how widespread prior patient use of incretins will affect prescribing. Naim states that many of his Rezdiffra MASH patients have been on GLP-1 already.  He describes a key difference between the three GLP/glucagon agents in development. 00:24:20 - The previous GLP/glucagon studiesNaim expresses his excitement about glucagon agents in general. He mentions that the efinopegdutide study included a semaglutide cell, which showed a further reduction in liver fat compared to the GLP-1 agent. 00:26:44 - Safety of survodutide in cirrhosisJörn comments on the high level of tolerability in the survodutide trials. Mazen shares his high hopes for GLP/glucagons and the triple agents. He reviews survodutide data from the NEJM article.  00:29:41 - FGF-21s, starting with efrux data Focus shifts to FGF-21s. Mazen shares data from the efruxifermin late-breaker, a 96-week, triple biopsy study showing dramatic, sustained one- and two-level fibrosis improvement. Jörn notes the design demonstrates durability, which Roger finds particularly encouraging given the pegbelfermin experience. Naim  adds that a sustainable two-stage drop in fibrosis might position FGF-21 as induction therapy before long-term oral maintenance.   00:35:28 - Is a drug-based MASH "cure" possible? Mazen wonders whether sustained FGF-21 efficacy might return livers to their "normal" state, almost like a "cure." Jörn briefly discusses pegozafermin, and Mazen notes that a third FGF-21 is in development.   00:42:22 - Wrap-up The panel covers three other agents: the FASN inhibitor, denifenstat, Ionis's DGAT-2 antisense inhibitor, ION224, and Takeda's TAK-227, a TG2 inhibitor, plus the results of SPECIAL, a study evaluating the effect of bariatric surgery on people with cirrhosis. After these, Roger asks Mazen and Jörn what they consider likely to be the biggest story at AASLD in November.  00:53:03 - Question of the Week Given this discussion, Roger asks what are likely to be the three most prescribed medications for MASH five years from now.  00:53:36 - Business Report The next EASL Congress review episodes, how to attend recording sessions live, and a vault discussion from last year's EASL Congress wrap-up. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XWR865. CME credit will be available until June 4, 2025.Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evolving Landscape of Glomerular Kidney Disease ManagementThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XWR865. CME credit will be available until June 4, 2025.Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evolving Landscape of Glomerular Kidney Disease ManagementThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XWR865. CME credit will be available until June 4, 2025.Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evolving Landscape of Glomerular Kidney Disease ManagementThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

In this excerpt from last July, Stephen Harrison shares results of the FASCINATE-2 study as part of SurfingMASH's larger coverage of exciting drug trials presented at The EASL Congress. The original writeup reads:This month, Surfing NASH embarks on a series of episodes dedicated to takeaways emerging from June's two major conferences: the 2023 EASL Congress in Vienna and the American Diabetes Association's 83rd Scientific Sessions meeting in San Diego. This is the second session focusing on drug development, and specifically, on several presentations for exciting drugs in development. In doing so, the Big Band of Surfers (Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green) are joined by Mazen Noureddin for a fascinating conversation which covers plenty of compelling clinical trial data.Jörn preludes this discussion by noting just how much important drug development research was released at this year's EASL Congress. Stephen proceeds from here to detail positive Phase 2b FASCINATE-2 clinical trial interim data for fatty acid synthase (FASN) inhibitor, denifanstat, as presented at EASL Congress by Rohit Loomba. In the process, Stephen elucidates why the idea of a FASN inhibitor is so exciting. It blocks de novo lipogenesis, which means it can have effects on inflammation and possibly direct fibrosis inhibition. Previously in Season 4, Episode 32, it was discussed why inflammation, which is tied to liver volume, might be a critical component to better understand for therapuetic development and the wider scope of liver health. From here, Stephen goes on to describe the trial, starting with basic design and sharing the MRI-PDFF and biomarker data that was presented at the EASL Congress. He finishes with safety and efficacy data and a general comment that the trial demonstrated, 'the drug is doing what it's intended.'

This episode is brought to you by Bioptimizers and Momentous.What if there was one key nutrient that could help improve your health, increase longevity, reduce chronic inflammation, and even reduce your risk for Alzheimer's? You've probably heard of this crucial nutrient: Omega-3! But did you know that over 90% of the population has suboptimal omega-3 levels? Today on The Dhru Purohit Podcast, Dhru sits down with Dr. Bill Harris, a world-renowned researcher, to discuss the decades of research he has conducted on omega-3s, and its correlation to longer life spans, reduced rates of depression, anxiety, and Alzheimer's, and reducing chronic inflammation. Dr. Harris shares that omega-3 is one of the most researched nutrients and one of the top three nutrients that can drastically improve our health. Dr. Harris shares his findings on what to look for in consuming quality fish, supplements, optimal levels, and how to test your levels via the OmegaQuant Institute.William S. Harris, PhD, FASN, has been a leading researcher in the omega-3 fatty acid field for 40 years. He has over 300 scientific papers on fatty acids and health, has been on the faculty of three medical schools, and received 5 NIH grants to study omega-3. He co-authored three AHA statements on fatty acids and heart health. As the co-inventor of the Omega-3 Index (and other omega-3 blood tests) and founder of OmegaQuant Analytics, Dr. Harris has been ranked among the top 2% of scientists worldwide based on the impact of his research. In this episode, Dhru and Dr. Harris dive into (audio version / Apple Subscriber version):Higher levels of omega-3's lead to a longer life (2:30 / 2:30)Omega-3s are in the top three nutrients that can improve our health (5:12 / 5:12)Mindblowing research on smokers and the protective nature of omega-3s (9:21 / 8:00)High levels of omega-3s and their correlation to reducing the risk for dementia and Alzheimer's (18:31 / 17:11)The research behind omega-3's and reducing chronic inflammation (22:42 / 21:22) The average omega-3 levels versus optimal levels (24:55 / 23:35) What are EPA, DHA, and ALA, and the sources of each (35:02 / 31:46) How much fish consumption is optimal, and what kind (43:01 / 39:39)Testing your levels via the Omega-3 index and optimal ranges (46:49 / 43:27)Algae-based oils and their impact on levels (56:04 / 52:34)Choosing the right fish oil and general dosage (59:15 / 55:54)Timeframe to reach optimal levels (1:15:30 / 1:12:26)Why the omega-3s aren't being tested for and prescribed by every doctor (1:24:25 / 1:21:04 )Also mentioned in this episode:Testing via OmegaQuantFatty Acid Research Insitute This episode is brought to you by Bioptimizers and Momentous. Start the New Year off right and dial in on your sleep. Go to bioptimizers.com/dhru now and enter promo code DHRU10 to get 10% off any order.Optimize your Omega-3 levels by choosing a quality fish oil made by and used by the best. Go to livemomentous.com and enter promo code DHRU to get 20% off any order. Hosted on Acast. See acast.com/privacy for more information.

End-stage renal disease is a dangerous reality for those who suffer from Lupus Nephritis (LN), despite improvements in immunosuppressive therapy in the last 20 years. Our next guest, Dr. Brad H Rovin, MD, FACP, FASN, is the first author of the manuscript “Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial.” which was recently published in Arthritis & Rheumatology. This study was a post hoc analysis of the NOBILITY trial and was conducted to assess kidney-related outcomes in patients using Obinutuzumab.